MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells

Marzia Pennati, Alessia Lopergolo, Valentina Profumo, Michelandrea De Cesare, Stefania Sbarra, Riccardo Valdagni, Nadia Zaffaroni, Paolo Gandellini, Marco Folini

Research output: Contribution to journalArticle

Abstract

Compelling evidence suggests that epithelial-to-mesenchymal transition is involved in the resistance of human cancer cells to chemotherapy. We previously reported that the expression of miR-205, a miRNA down-regulated in prostate cancer, is further repressed in prostate cancer cells undergoing epithelial-to-mesenchymal transition, suggesting a possible involvement of the miRNA in the acquisition of the chemoresistant phenotype. In the present study, we show that miR-205 replacement in castration-resistant mesenchymal prostate cancer cells caused an enhancement of cisplatin cytotoxic activity in vitro and in vivo, as a consequence of autophagy impairment. Specifically, the constraints on the autophagic flux were associated to the miRNA-dependent down-regulation of the lysosome-associated proteins RAB27A and LAMP3. These findings suggest that miR-205-mediated impairment of the autophagic pathway may interfere with the detoxifying capabilities of prostate cancer cells in their attempt to cope with cisplatin-induced detrimental effects. Overall, our data indicate that (i) loss of miR-205 may indeed contribute to acquire mesenchymal tracts and concomitantly establish a permissive autophagic milieu that confers a chemotherapy resistant phenotype to prostate cancer cells, and (ii) strategies aimed at restoring miR-205 expression levels may represent a successful approach to overcome resistance of prostate cancer to platinum compounds.

Original languageEnglish
Pages (from-to)579-597
Number of pages19
JournalBiochemical Pharmacology
Volume87
Issue number4
DOIs
Publication statusPublished - Feb 15 2014

Fingerprint

Castration
Cytotoxicity
Cisplatin
Prostatic Neoplasms
MicroRNAs
Cells
Fluxes
Chemotherapy
Epithelial-Mesenchymal Transition
Platinum Compounds
Phenotype
Drug Therapy
Autophagy
Lysosomes
Down-Regulation
Proteins
Neoplasms

Keywords

  • Autophagy
  • Cisplatin
  • LAMP3
  • miR-205
  • Prostate cancer
  • RAB27A

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. / Pennati, Marzia; Lopergolo, Alessia; Profumo, Valentina; De Cesare, Michelandrea; Sbarra, Stefania; Valdagni, Riccardo; Zaffaroni, Nadia; Gandellini, Paolo; Folini, Marco.

In: Biochemical Pharmacology, Vol. 87, No. 4, 15.02.2014, p. 579-597.

Research output: Contribution to journalArticle

Pennati, Marzia ; Lopergolo, Alessia ; Profumo, Valentina ; De Cesare, Michelandrea ; Sbarra, Stefania ; Valdagni, Riccardo ; Zaffaroni, Nadia ; Gandellini, Paolo ; Folini, Marco. / MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. In: Biochemical Pharmacology. 2014 ; Vol. 87, No. 4. pp. 579-597.
@article{48dd39162d6f41d985ec8e92f0c62fe3,
title = "MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells",
abstract = "Compelling evidence suggests that epithelial-to-mesenchymal transition is involved in the resistance of human cancer cells to chemotherapy. We previously reported that the expression of miR-205, a miRNA down-regulated in prostate cancer, is further repressed in prostate cancer cells undergoing epithelial-to-mesenchymal transition, suggesting a possible involvement of the miRNA in the acquisition of the chemoresistant phenotype. In the present study, we show that miR-205 replacement in castration-resistant mesenchymal prostate cancer cells caused an enhancement of cisplatin cytotoxic activity in vitro and in vivo, as a consequence of autophagy impairment. Specifically, the constraints on the autophagic flux were associated to the miRNA-dependent down-regulation of the lysosome-associated proteins RAB27A and LAMP3. These findings suggest that miR-205-mediated impairment of the autophagic pathway may interfere with the detoxifying capabilities of prostate cancer cells in their attempt to cope with cisplatin-induced detrimental effects. Overall, our data indicate that (i) loss of miR-205 may indeed contribute to acquire mesenchymal tracts and concomitantly establish a permissive autophagic milieu that confers a chemotherapy resistant phenotype to prostate cancer cells, and (ii) strategies aimed at restoring miR-205 expression levels may represent a successful approach to overcome resistance of prostate cancer to platinum compounds.",
keywords = "Autophagy, Cisplatin, LAMP3, miR-205, Prostate cancer, RAB27A",
author = "Marzia Pennati and Alessia Lopergolo and Valentina Profumo and {De Cesare}, Michelandrea and Stefania Sbarra and Riccardo Valdagni and Nadia Zaffaroni and Paolo Gandellini and Marco Folini",
year = "2014",
month = "2",
day = "15",
doi = "10.1016/j.bcp.2013.12.009",
language = "English",
volume = "87",
pages = "579--597",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - MiR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells

AU - Pennati, Marzia

AU - Lopergolo, Alessia

AU - Profumo, Valentina

AU - De Cesare, Michelandrea

AU - Sbarra, Stefania

AU - Valdagni, Riccardo

AU - Zaffaroni, Nadia

AU - Gandellini, Paolo

AU - Folini, Marco

PY - 2014/2/15

Y1 - 2014/2/15

N2 - Compelling evidence suggests that epithelial-to-mesenchymal transition is involved in the resistance of human cancer cells to chemotherapy. We previously reported that the expression of miR-205, a miRNA down-regulated in prostate cancer, is further repressed in prostate cancer cells undergoing epithelial-to-mesenchymal transition, suggesting a possible involvement of the miRNA in the acquisition of the chemoresistant phenotype. In the present study, we show that miR-205 replacement in castration-resistant mesenchymal prostate cancer cells caused an enhancement of cisplatin cytotoxic activity in vitro and in vivo, as a consequence of autophagy impairment. Specifically, the constraints on the autophagic flux were associated to the miRNA-dependent down-regulation of the lysosome-associated proteins RAB27A and LAMP3. These findings suggest that miR-205-mediated impairment of the autophagic pathway may interfere with the detoxifying capabilities of prostate cancer cells in their attempt to cope with cisplatin-induced detrimental effects. Overall, our data indicate that (i) loss of miR-205 may indeed contribute to acquire mesenchymal tracts and concomitantly establish a permissive autophagic milieu that confers a chemotherapy resistant phenotype to prostate cancer cells, and (ii) strategies aimed at restoring miR-205 expression levels may represent a successful approach to overcome resistance of prostate cancer to platinum compounds.

AB - Compelling evidence suggests that epithelial-to-mesenchymal transition is involved in the resistance of human cancer cells to chemotherapy. We previously reported that the expression of miR-205, a miRNA down-regulated in prostate cancer, is further repressed in prostate cancer cells undergoing epithelial-to-mesenchymal transition, suggesting a possible involvement of the miRNA in the acquisition of the chemoresistant phenotype. In the present study, we show that miR-205 replacement in castration-resistant mesenchymal prostate cancer cells caused an enhancement of cisplatin cytotoxic activity in vitro and in vivo, as a consequence of autophagy impairment. Specifically, the constraints on the autophagic flux were associated to the miRNA-dependent down-regulation of the lysosome-associated proteins RAB27A and LAMP3. These findings suggest that miR-205-mediated impairment of the autophagic pathway may interfere with the detoxifying capabilities of prostate cancer cells in their attempt to cope with cisplatin-induced detrimental effects. Overall, our data indicate that (i) loss of miR-205 may indeed contribute to acquire mesenchymal tracts and concomitantly establish a permissive autophagic milieu that confers a chemotherapy resistant phenotype to prostate cancer cells, and (ii) strategies aimed at restoring miR-205 expression levels may represent a successful approach to overcome resistance of prostate cancer to platinum compounds.

KW - Autophagy

KW - Cisplatin

KW - LAMP3

KW - miR-205

KW - Prostate cancer

KW - RAB27A

UR - http://www.scopus.com/inward/record.url?scp=84893731055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893731055&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2013.12.009

DO - 10.1016/j.bcp.2013.12.009

M3 - Article

C2 - 24370341

AN - SCOPUS:84893731055

VL - 87

SP - 579

EP - 597

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -